Is Egrifta (Tesamorelin) Legal in Alabama?

The Short Answer: Yes, Tesamorelin Is Legal in Alabama

Egrifta is legal in Alabama. The drug received FDA approval in November 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Because it is an approved prescription drug, not a research chemical or unapproved peptide, the legal framework is straightforward: a licensed Alabama prescriber writes the prescription, and a licensed pharmacy dispenses it.

Alabama has no separate state statute that restricts tesamorelin beyond federal requirements. The Alabama State Board of Pharmacy regulates dispensing under the Alabama Pharmacy Practice Act, which defers to FDA approval status. Tesamorelin is not listed on the DEA controlled substances schedule, so there is no additional permit or triplicate-prescription requirement.

That legal clarity matters because the broader peptide market is full of products sitting in genuine legal gray zones. Tesamorelin is not one of them.

Federal Framework: FDA Approval vs. Unapproved Peptides

The FDA's legal pathway for peptides breaks into two categories: approved drugs and everything else.

Approved drugs, like Egrifta, go through a New Drug Application (NDA) and carry a specific, labeled indication. They can be prescribed off-label by any licensed clinician. Unapproved peptides, by contrast, have faced increasing FDA enforcement. The FDA's 2023 and 2024 guidance documents have placed numerous compounded peptides, including BPC-157 and CJC-1295, on the FDA bulks list review track, meaning their legal status in compounding pharmacies is actively contested.

Tesamorelin sits outside that contested zone because its branded form, Egrifta, cleared the NDA process. A 503A compounding pharmacy in Alabama could, in principle, compound tesamorelin for an individual patient with a valid prescription if a demonstrable clinical need exists and the compound is not essentially a copy of the commercially available product. A 503B outsourcing facility may compound it under separate FDA conditions. But for most Alabama patients, the commercially available Egrifta product is what prescribers order.

Alabama State Pharmacy Law: What It Actually Says

Alabama's Pharmacy Practice Act, governed by the Board of Pharmacy, does not enumerate individual approved drug molecules as restricted or permitted beyond the DEA schedule. Because tesamorelin is not scheduled, an Alabama pharmacist may dispense it on a standard prescription. The physician or advanced practice clinician who prescribes it operates under the Alabama Medical Licensure Commission's standard of care rules, which allow off-label prescribing when medically justified and documented.

There is no Alabama-specific tesamorelin ban, no state-level scheduling action, and no pending legislative restriction as of the date this article was reviewed.

What Egrifta (Tesamorelin) Actually Does: The Physiology

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds to pituitary GHRH receptors and stimulates pulsatile release of endogenous growth hormone (GH). That GH then drives hepatic production of insulin-like growth factor-1 (IGF-1), which reduces visceral adipose tissue (VAT).

The Phase 3 LIPO trials demonstrated that tesamorelin 2 mg subcutaneously once daily reduced visceral adipose tissue by approximately 18% over 26 weeks in adults with HIV-associated lipodystrophy, compared with placebo. A reduction of that magnitude, roughly 18 cm² on CT cross-section, is clinically meaningful for cardiometabolic risk.

Why the Growth Hormone Axis Matters Differently for Women

Women have a naturally higher GH pulse amplitude than men but also experience more pronounced GH axis suppression after menopause. Research published in the Journal of Clinical Endocrinology and Metabolism shows that GH secretion declines by roughly 14% per decade in adult women, with an accelerated drop in the perimenopausal transition. This means the tissue a tesamorelin prescription targets, visceral fat, also expands preferentially in women after menopause.

Estrogen modulates GH sensitivity. During the reproductive years, oral estrogen reduces hepatic IGF-1 production because of first-pass metabolism, a phenomenon that does not occur with transdermal estrogen. A woman on oral estrogen therapy who also takes a GHRH analog may see a blunted IGF-1 rise compared with a woman on transdermal estrogen or no estrogen at all. Prescribers managing perimenopausal or postmenopausal women who want tesamorelin should factor in the route of estrogen delivery when monitoring IGF-1 levels.

Visceral Fat and the Female Metabolic Pattern

Premenopausal women generally store more subcutaneous fat than visceral fat relative to men of comparable BMI. After menopause, that distribution shifts: visceral adipose tissue increases, and the cardiometabolic risk that comes with it rises sharply. By age 60, women's visceral fat burden approaches that of age-matched men, according to data from the Framingham Heart Study offspring cohort.

Women with PCOS represent a separate high-risk group. Hyperandrogenism in PCOS is associated with preferential visceral fat accumulation even in premenopausal women with normal BMI. No trial to date has evaluated tesamorelin specifically in women with PCOS. That evidence gap is real, and anyone offering tesamorelin to a woman with PCOS for visceral fat reduction is doing so on extrapolated, not direct, evidence.

Who Is Egrifta Approved For, and Who Gets It Off-Label?

The only FDA-approved indication is reduction of excess abdominal fat in HIV-positive adults with lipodystrophy. This is a specific metabolic complication of antiretroviral therapy, not general obesity.

On-Label Use in Alabama Women Living With HIV

HIV-positive women on antiretroviral therapy who develop lipodystrophy are squarely within the approved population. Alabama had an estimated 7,800 people living with HIV as of 2021, and women represent a meaningful share of that population in the South, where HIV rates among women, particularly Black women, remain disproportionately high. For these women, tesamorelin at 2 mg subcutaneously once daily is standard of care under the approved label.

Off-Label Use: What Prescribers Actually Do

Outside the HIV lipodystrophy context, some obesity medicine specialists and anti-aging clinicians prescribe tesamorelin off-label for visceral fat reduction in non-HIV adults. This is legal in Alabama and across the United States. Off-label prescribing is a routine clinical practice. It requires informed consent and documentation of clinical reasoning. It does not require any special state permit.

A clinically defensible framework for off-label tesamorelin in women might include: documented excess visceral adiposity (by DEXA or waist circumference above 88 cm), GH axis evaluation ruling out frank acromegaly, baseline IGF-1 within or below the reference range for age, no active malignancy, and explicit counseling that the evidence base is drawn primarily from HIV-positive adult trials rather than general-population female studies.

How to Get Egrifta in Alabama: The Prescription Pathway

Getting tesamorelin in Alabama follows the same path as any brand-name specialty medication.

Finding a Prescriber

A board-certified physician, physician assistant, or nurse practitioner with a valid Alabama license may prescribe Egrifta. Prescribers who commonly order it include endocrinologists, infectious disease specialists (for HIV lipodystrophy), and, for off-label use, obesity medicine physicians and some women's health specialists. WomanRx telehealth clinicians licensed in Alabama can evaluate whether tesamorelin fits your clinical picture during an asynchronous or synchronous visit.

The Pharmacy and Insurance Question

Egrifta is available through specialty pharmacies. The manufacturer's patient assistance program exists for eligible patients, though formulary coverage for the HIV lipodystrophy indication varies by insurer. Off-label prescriptions are rarely covered by insurance. Out-of-pocket costs for Egrifta can be substantial, which is one reason some patients and prescribers look to compounded tesamorelin from 503A pharmacies. That pathway is legal if the pharmacy is properly licensed and the prescription is patient-specific.

Ask your pharmacy whether it holds an Alabama Board of Pharmacy permit. A quick verification is available through the Alabama Board of Pharmacy license lookup.

Telehealth Prescribing in Alabama

Alabama participates in interstate telehealth prescribing, and a clinician licensed in Alabama can prescribe Egrifta during a telehealth visit if she or he has established a valid patient-provider relationship. The Alabama Telehealth Act requires that telehealth services meet the same standard of care as in-person care. No additional prescribing restrictions apply to tesamorelin specifically.

Pregnancy, Lactation, and Contraception: Required Reading

Tesamorelin is contraindicated in pregnancy. This is not a borderline safety concern. Here is what the data actually show.

Pregnancy Safety

The FDA-approved Egrifta label states that animal reproduction studies showed fetal harm at doses below the human therapeutic dose, and there are no adequate, well-controlled studies in pregnant women. The drug is classified under the pre-PLLR system as Pregnancy Category X for this indication context, meaning the risks outweigh any potential benefit.

If you are pregnant, do not use tesamorelin. If you are of reproductive age and using tesamorelin, you need reliable contraception. This is not a "be careful" situation. The prescribing label is explicit, and the standard of care in reproductive-age women requires contraception counseling before and during treatment.

Women in the perimenopause transition who still have menstrual cycles, even irregular ones, retain the possibility of pregnancy and should be treated as reproductive-age until menopause is confirmed by 12 consecutive months of amenorrhea.

Lactation

No human data exist on tesamorelin transfer into breast milk. The label states that because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug. WomanRx recommends against tesamorelin during breastfeeding. Postpartum and lactating women should defer this medication until they have weaned.

Trying to Conceive

Women actively trying to conceive should stop tesamorelin before attempting pregnancy. Given that the drug's mechanism involves pulsatile GH stimulation, and that GH axis perturbations could theoretically affect follicular development or endometrial receptivity, there is a biologically plausible concern beyond the direct teratogenicity signal. No human fertility trial data exist specifically for tesamorelin. Discontinue at least one full menstrual cycle before conception attempts, though this conservative recommendation is extrapolated from general peptide pharmacology rather than from a controlled trial.

Dosing, Monitoring, and Female-Specific Considerations

The approved dose is 2 mg subcutaneously once daily, injected into the abdomen. Rotation of injection sites is standard. The drug is supplied as a lyophilized powder requiring reconstitution.

IGF-1 Monitoring

Baseline IGF-1 should be measured before starting. Repeat IGF-1 at 6 weeks and 3 months. A target of the upper third of the age- and sex-specific normal range is reasonable for most patients. Values consistently above the upper limit of normal suggest dose reduction or discontinuation.

Women's IGF-1 reference ranges are age-adjusted and sex-specific. The ranges differ from those used in male patients, and using a male-default reference range to interpret a woman's IGF-1 level is an error that women's health clinicians should actively avoid. Reference ranges from the IGF-1 normative data published in JCEM differentiate by both age and sex.

Menstrual Cycle Effects

No published trial has systematically tracked menstrual cycle changes in women on tesamorelin. GH axis activation can, in theory, affect LH and FSH pulsatility. Women who notice menstrual irregularity after starting tesamorelin should report it to their prescriber. That information gap is real: the key LIPO trials did not include sufficient numbers of premenopausal women to generate menstrual cycle safety data.

Side Effects More Relevant to Women

Fluid retention and edema occur in roughly 10-18% of trial participants, based on LIPO trial safety data. Women with a history of cyclic edema, those on oral estrogen (which itself promotes sodium retention), or women in the luteal phase of their cycle may experience more pronounced fluid retention. Joint pain (arthralgia) and carpal tunnel syndrome are also GH-class effects that women report at rates similar to or slightly higher than men in the general GH therapy literature, though tesamorelin-specific sex-stratified adverse event data remain limited.

Who This Is Right For, and Who Should Not Use It

Women Who May Benefit

• HIV-positive women on antiretroviral therapy with documented lipodystrophy. This is the on-label group with the strongest evidence.
• Postmenopausal women with elevated visceral adiposity who have been evaluated by an obesity medicine or endocrinology specialist, have a documented clinical rationale, and understand the off-label nature of the use.
• Women with GH deficiency confirmed by provocative testing who are not candidates for recombinant GH and whose clinician chooses tesamorelin as an off-label secretagogue approach.

Women Who Should Not Use It

• Pregnant women. Absolute contraindication.
• Breastfeeding women. Avoid.
• Women with active or suspected malignancy. GH stimulation in the presence of active cancer is a clinical red line across all GH-axis agents.
• Women with hypothalamic or pituitary tumors that could be stimulated by GHRH agonism.
• Women with severe diabetic retinopathy.
• Women with pituitary insufficiency, where the GHRH receptor population may be insufficient for a meaningful response.
• Women who have not had contraception counseling and are of reproductive age.

As ACOG's guidance on off-label drug use in obstetrics and gynecology notes, off-label prescribing is permissible when the clinician is well-informed, bases the decision on sound evidence, and obtains meaningful informed consent. That framework applies here.

Evidence Gaps: What We Know and What Is Extrapolated

Women have been historically underrepresented in metabolic and GH-axis trials. A 2021 analysis in JAMA Internal Medicine found that women represent fewer than 40% of participants in major cardiovascular and metabolic trials, and the enrollment gap widens in specialized peptide and GH research.

For tesamorelin specifically:

• Directly studied in women: HIV lipodystrophy reduction, overall safety profile, IGF-1 pharmacodynamics (though not always sex-stratified in the published data).
• Extrapolated from men or general populations: Off-label visceral fat reduction in non-HIV adults, effects across the menstrual cycle, PCOS-specific metabolic effects, postmenopausal dosing optimization, long-term malignancy risk beyond 52-week trial duration.

That honest accounting is not a reason to avoid tesamorelin when it is clinically indicated. It is a reason to monitor carefully, document outcomes, and participate in the kind of real-world data collection that will eventually close these gaps.

A Clinician's Perspective on Tesamorelin for Women in Alabama

"The conversation I have with patients about tesamorelin always starts with the same question: are we treating a documented condition, or chasing a goal that a better-studied intervention could reach?" says Maya Okafor, MD, WomanRx Medical Reviewer and board-certified OB-GYN. "For women with HIV lipodystrophy, the answer is clear. For a perimenopausal woman who wants to reduce visceral fat, I want to see her menopause hormone therapy optimized first, her insulin resistance addressed, and her activity pattern documented before we add a GHRH analog to the picture."

That staged approach reflects the current standard of care: tesamorelin is not a first-line metabolic intervention for most women, but it occupies a real and legal clinical space for the right patient.